Ogawa M, Kubo K, Tominaga T, Nomura Y, Ota K, Yoshida M, Taguchi T, Hoshino A
Gan To Kagaku Ryoho. 1986 May;13(5):1980-4.
A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions. Mitoxantrone was administered at doses of 10-12 mg/m2 at 3-4-week intervals. A total of 36 patients were entered and 31 were evaluable. There were 4 CRs (13%) and 3 PRs (10%) with an overall response rate of 23% and the durations of responses were between 6 and 25 weeks. Leukopenia was a dose-limiting effect of toxicity and occurred in all patients, while gastrointestinal toxicity and alopecia were mild.
一个由7家机构组成的合作研究小组对米托蒽醌治疗晚期乳腺癌进行了一项II期研究。米托蒽醌以10 - 12mg/m²的剂量，每3 - 4周给药一次。总共纳入36例患者，其中31例可评估。有4例完全缓解（13%）和3例部分缓解（10%），总缓解率为23%，缓解持续时间在6至25周之间。白细胞减少是毒性的剂量限制性效应，所有患者均出现，而胃肠道毒性和脱发较轻。
